

INDEX

1. Introduction	1
1.1 <i>Bioavailability and its importance</i>	1
1.1.1 Techniques for improving oral Bioavailability	2
1.1.2 Necessity to develop nanoparticle based drug delivery	2
1.1.3 Solubility problem for antiretroviral Drugs	3
1.1.4 Nanoparticles and Antiretroviral Drugs	4
1.2 <i>Mesoporous Materials</i>	5
1.2.1 Nomenclature of Mesoporous Materials	5
1.2.2 Advantage of MSNs and as drug carriers	6
1.3 <i>Synthesis of Mesoporous Silica Materials</i>	7
1.4 <i>Characterization of Mesoporous silica nanoparticles</i>	11
1.4.1 Powder X-ray Diffraction (PXRD)	11
1.4.2 Nitrogen Sorption Analysis	12
1.4.3 Scanning Electron Microscopy (SEM)	14
1.4.4 Transmission Electron Microscopy (TEM)	15
1.4.5 Fourier transforms infrared spectroscopy (FTIR)	15
1.5 <i>Mesoporous Materials and Drug</i>	15
1.5.1 Drug Loading in Mesoporous drug carrier systems	15
1.5.2 Drug Loading Methods	16
1.5.3 Confirmation of Drug Loading	19
1.6 <i>Mesoporous silica nanoparticles: Use as a Solubility Enhancer carrier</i>	20
1.7 <i>Studies on effect on oral drug bioavailability</i>	22
1.8 <i>Physical and chemical stability of drug-loaded product</i>	24
1.9 <i>Biocompatibility and Toxicity</i>	25
1.9.1 Safety assessment of mesoporous materials	25
1.9.2 Toxicity of Mesoporous silica nanoparticles	26
References	29
2. Aims and Objectives	47
3. Literature Review	49
3.1 <i>Selection of Drugs</i>	49
3.2 <i>Literature Review for Drugs</i>	49
3.3 <i>Mesoporous Silica Nanoparticles</i>	50
4. Development and Validation of Analytical Methods	56
4.1 Development and Validation of Analytical Methods for Ritonavir	56
4.1.1 <i>UV-Spectrophotometric Method for Ritonavir</i>	56
4.1.1.1 Materials and methods	56
4.1.1.2 Analytical Method Validation	57
4.1.2 <i>HPLC Method for Ritonavir</i>	60
4.1.2.1 Materials and methods	60
4.1.2.2 Method for RTV by RP-HPLC	60
4.1.2.3 RP-HPLC Analytical Method Validation	61
4.1.3 <i>HPLC Method for Estimation of RTV in Plasma</i>	64
4.1.3.1 Experimental	64
4.1.3.2 Bio-analytical Method Validation	65

4.1.3.3 Stability study of RTV samples	66
4.1.4 <i>Results and Discussion</i>	66
4.1.5 <i>Conclusion</i>	71
<i>References</i>	72
4.2 Development and Validation of Analytical Methods for Lopinavir	76
4.2.1 <i>UV-Spectrophotometric Method for Lopinavir</i>	76
4.2.1.1 Materials and methods	76
4.2.1.2 Analytical Method Validation	77
4.2.2 <i>HPLC method for Lopinavir</i>	80
4.2.2.1 Materials and methods	80
4.2.2.2 Method of LPV by RP-HPLC	80
4.2.2.3 RP-HPLC Analytical Method Validation	81
4.2.3 <i>HPLC Method for Estimation of LPV in Plasma</i>	83
4.2.4 <i>Conclusion</i>	89
5. Ritonavir and MSNs	94
Experimental	94
5.1 <i>Synthesis of Mesoporous Silica Nanoparticles (MSNs)</i>	94
5.1.1 Materials	94
5.1.2 Synthesis procedure for various Mesoporous Silica Nanoparticles (MSNs)	94
5.2 <i>Characterization of synthesized MSNs</i>	95
5.2.1 Scanning Electron Microscopy (SEM)	95
5.2.2 Transmission Electron Microscopy (TEM)	95
5.2.3 FT-IR analysis	95
5.2.4 Differential Scanning Calorimetry (DSC)	95
5.2.5 Powder X-ray diffraction (PXRD)	96
5.2.6 N ₂ Adsorption-desorption analysis	96
5.3 <i>RTV loading in mesoporous silica nanoparticles (MSNs)</i>	96
5.4 <i>Characterization of RTV loaded Mesoporous silica nanoparticles (R-MSNs-NPs)</i>	97
<i>Total weight of sample</i>	97
5.5 <i>Formulation of R-MSNs tablet and evaluation</i>	97
5.6 <i>In-vitro dissolution study</i>	98
5.7 <i>In-vivo pharmacokinetic study for RTV</i>	98
5.7.1 Animals	99
5.7.2 Experimental: Dosing and sampling	100
5.7.3 Instrumental and statistical analysis	100
5.8 <i>Cell Line Studies of RTV and it's formulations using Caco-2 cell line model</i>	100
5.8.1 Principle of MTT Assay	101
5.8.2 Experiment	102
5.9 <i>Stability study of R-MSNs</i>	103
5.9.1 Significance of stability testing	103
5.9.2 Method for stability sample preparation and evaluation	104

RESULT AND DISCUSSION	105
5.10 <i>Synthesis of MCM-41NPs, MCM-48NPs and SBA-15NPs (MSNs)</i>	105
5.11 <i>Characterization of MCM-48NPs, MCM-41NPs and SBA-15NPs (MSNs)</i>	105
5.11.1 SEM and TEM of MSNs	105
5.11.2 FT-IR of MSNs	106
5.11.3 Powder X-ray Diffraction of MSNs	107
5.11.4 N ₂ Adsorption desorption analysis	107
5.12 <i>RTV loading in Mesoporous Silica Nanoparticles (MSNs)</i>	109
5.13 <i>Optimization of drug loading procedure</i>	110
5.13.1 Ratio of drug to carrier	110
5.13.2 Thermogravimetric Analysis	112
5.14 <i>Characterization and Evaluation of R-MCM-48NPs, R-MCM-41NPs and R-SBA-15NPs (R-MSNs)</i>	113
5.14.1 Transmission electron microscopy (TEM)	113
5.14.2 FTIR analysis	114
5.14.3 Differential Scanning Calorimetry (DSC)	116
5.14.4 Powder X-ray diffraction (XRD)	117
5.14.5 Nitrogen adsorption isotherm (BET surface analysis)	118
5.15 <i>Tablet Formulations of R-MCM-48NPs, R-MCM-41NPs and R-SBA-15NPs (R-MSNs-NPs)</i>	120
5.16 <i>In-vitro dissolution study</i>	121
5.17 <i>In-vivo study</i>	122
5.18 <i>In vitro Cell Cytotoxicity Studies (MTT Assay)</i>	124
5.19 <i>Stability Study</i>	125
5.19.1 Physical Stability	125
5.19.2 Chemical Stability	129
<i>Summery and Conclusion</i>	130
<i>References</i>	132
6. Lopinavir and MSNs	137
Experimental	137
6.1 <i>Synthesis procedure for MCM-41NPs, MCM-48NPs and SBA-15NPs</i>	137
6.2 <i>Characterization of Mesoporous MCM-41NPs</i>	137
6.3 <i>LPV loading in mesoporous silica nanoparticles (MSNs)</i>	137
6.4 <i>Characterization of LPV loaded Mesoporous silica nanoparticles (L-MSNs-NPs)</i>	138
6.5 <i>Formulation of L-MSNs and LR-MSNs tablet and evaluation</i>	138
6.6 <i>In-vitro dissolution study</i>	139
6.7 <i>In-vivo pharmacokinetic study for LPV</i>	140
6.8 <i>Cell Line Studies of LPV and it's formulations using Caco-2 cell line model</i>	141
6.9 <i>Stability study of L-MSNs</i>	141
RESULT AND DISCUSSION	142
6.10 <i>Synthesis of MCM-41NPs, MCM-48NPs and SBA-15NPs (MSNs)</i>	142
6.11 <i>Characterization of MCM-48NPs, MCM-41NPs and SBA-15NPs (MSNs)</i>	142
6.12 <i>LPV loading in Mesoporous Silica Nanoparticles (MSNs)</i>	142

6.13 <i>Optimization of drug loading procedure</i>	142
6.13.1 Ratio of drug to carrier	142
6.13.2 Thermogravimetric Analysis	144
6.14 <i>Characterization and Evaluation of L-MCM-48NPs, L-MCM-41NPs and L-SBA-15NPs (L-MSNs)</i>	145
6.14.1 Transmission electron microscopy (TEM)	146
6.14.2 FTIR analysis	146
6.14.3 Differential Scanning Calorimetry (DSC)	148
6.14.4 Powder X-ray diffraction (XRD)	149
6.14.5 Nitrogen adsorption isotherm (BET surface analysis)	150
6.15 <i>Tablet Formulation of L-MCM-48NPs, L-MCM-41NPs and L-SBA-15NPs (L-MSNs)</i>	152
6.15.1 Tablet Formulation of L-MSNs and R-MSNs	153
6.16 <i>In-vitro dissolution study of LPV</i>	153
6.17 <i>In-vivo study of LPV</i>	155
6.18 <i>In vitro Cell Cytotoxicity Studies of L-MSNs (MTT Assay)</i>	158
6.19 <i>Stability Study</i>	159
6.19.1 Physical Stability	159
6.20.2 Chemical Stability	163
<i>Summery and Conclusion</i>	164
<i>References</i>	167
Summary and Conclusion	169